# BM-PHASE-012-FINAL-REPORT — End-to-End Production Validation

## Delivery Summary

| Criterion | Result |
|---|---|
| Phase | 012 — End-to-End Production Validation |
| Date | 2026-07-29 |
| Status | **DELIVERED** — STOP before Phase 013 |
| Reports | 9 (A through I) |
| Critical bug found | 1 duplicate type (fixed) |
| Other findings | 10 (documented) |

## What Was Audited

### A — Architecture Audit ✅
Clean dependency graph (no circular dependencies). 15 interfaces with implementations. 8 interfaces without implementations (all low-impact). **1 CRITICAL finding: `ChifaValidationError` defined twice in same namespace** — fixed. 4 unregistered service classes (all test-only). `MainViewModel` DI bypass.

### B — Workflow Audit ✅
Complete 5-phase workflow documented (Preparation → Persistence → Visibility → Synchronization → Bordereau). 13 invoice states, 7 bordereau states. All preconditions, postconditions, and error transitions documented.

### C — Exception Audit ✅
7 exception types documented with origin, propagation, retry, and rollback behavior. CircuitBreaker integration documented. All exceptions properly caught at facade level.

### D — Performance Review ✅
No N+1 queries found. `AsNoTracking` used correctly in read contexts. Memory analysis shows bounded growth for all components (minor recommendations for capping metrics). No tracking waste.

### E — Security Review ✅
ReadOnly mode and WriteGuard effective. **High risk: PostgreSQL superuser (pharm) with trust auth.** Token isolated in CHIFA-OFFICINE. No SQL injection risk (EF Core parameterized). Connection string in plain config — needs User Secrets or env variable.

### F — Production Readiness ✅
4 readiness levels assessed. Internal Experimentation: GO. Pilot Pharmacy: GO WITH LIMITATIONS (7 conditions). Daily Use: NO GO (10 unmet requirements). Production: NO GO.

### G — Test Coverage ✅
630 `[Fact]` tests across 27 files. All Phase 011 components fully covered. Gaps: no E2E integration test with real PG, no concurrent write test, no performance benchmark.

### H — Documentation Consistency ✅
Phase 010 + 011 documentation complete. Phase 001-008 not in workspace. 1 contradiction found (TST003 root cause — corrected). Test count under-reported in Phase 011 docs (593 stated, actual 630).

### I — Final Assessment ✅
```
Internal Experimentation:  ✅ GO
Pilot Pharmacy:            ⚠️ GO WITH LIMITATIONS (7 conditions)
Daily Use:                 ❌ NO GO
Production:                ❌ NO GO
```

## Critical Issue Fixed

**`ChifaValidationError` duplicate in `BMPharma.CHIFA.Services` namespace:**
- `ChifaExceptions.cs:17` — removed (duplicate)
- `ChifaInvoiceValidator.cs:118` — kept (original)

## Open Items (Phase 013 potential)

| Item | Priority |
|---|---|
| Create restricted PostgreSQL role for BM Pharma | P0 |
| Upgrade PostgreSQL to 64-bit v15+ | P0 |
| Replace trust auth with md5/scram-sha-256 | P0 |
| Move connection string to User Secrets | P0 |
| Add automated deployment script | P1 |
| Add E2E integration test | P2 |
| Consolidate `ChifaConcurrencyException` | P2 |
| Fix `ChifaNumberingService.cs` namespace | P2 |
| Fix `MainViewModel` DI | P3 |

## STOP

**Phase 012 is complete.** Do NOT proceed to Phase 013 without explicit approval.

Total artifacts: 11 (9 reports + INDEX + FINAL-REPORT)
